Abareliks
Klinički podaci | |||
---|---|---|---|
AHFS/Drugs.com | Monografija | ||
Identifikatori | |||
CAS broj | 183552-38-7 | ||
ATC kod | L02BX01 | ||
PubChem[1][2] | 16131215 | ||
DrugBank | DB00106 | ||
ChemSpider[3] | 10482301 | ||
ChEBI | CHEBI:337298 Y | ||
ChEMBL[4] | CHEMBL1252 Y | ||
Hemijski podaci | |||
Formula | C72H95ClN14O14 | ||
Mol. masa | 1416,06 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakokinetički podaci | |||
Poluvreme eliminacije | 3,2 dana | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Intramaskularno |
Abareliks (Plenaxis) injektivni je antagonist gonadotropin-oslobađajućeg hormona (GnRH antagonist). On se prvenstveno koristi u onkologiji za redukivanje količine testosterona formiranog u pacijentija sa naprednom simptomatskom raka prostate za koji drugi tretmani nisu dostupni.[5][6][7][8]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Drugs.com: Abarelix Arhivirano 2018-02-10 na Wayback Machine-u
- ↑ Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). „An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer”. Therapeutic Advances in Urology 3 (3): 127–140. DOI:10.1177/1756287211414457. PMC 3159401. PMID 21904569.
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. edit
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. edit
Literatura
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
Spoljašnje veze
Portal Medicina | |
Portal Hemija |
Abareliks na Wikimedijinoj ostavi
- Abarelix